You have read all your free articles, to continue reading subscribe to read the rest of this content.
NeuroVive Pharmaceutical announces that an abstract with novel preclinical cancer data related to the company's sanglifehrin-based compounds has been accepted for presentation at the scientific conference EASL HCC Summitto take place in Geneva, Switzerland, 2-5 February, 2017. In preclinical studAlready a subscriber Login You have read all your free articles,…
New data from an ongoing post-marketing study evaluating the safety of once-daily XARELTO® (rivaroxaban) in patients with non-valvular atrial fibrillation (NVAF) were presented at the American Geriatrics Society 2015 Annual Scientific Meeting. "The data from this ongoing five-year observational Already a subscriber Login You have read all your free articles,…
Data from a voluntary open label extension (OLE) study indicates longer PSA effect with Liproca Depot in prostate cancer patients than anticipated. In half of the patients it has taken between 8 to 10 months from the initial Liproca Depot injection until they have returned to the same PSA levels…
Affibody’s licensee Rallybio Corporation has announced positive topline results from a Phase 1 single ascending dose (SAD) study in healthy participants of RLYB116. In the ongoing Phase 1 study, all study participants that were administered a single 1 mL subcutaneous injection of 100 mg of RLYBAlready a subscriber Login You…
